Kornimate/medical-research-clean huggingface dataset:
a study to evaluate the safety and tolerability of bms-986403 in participants with relapsed and/or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma

Summary: the purpose of this study is to evaluate the safety and preliminary efficacy of bms-986403 in participants with relapsed and/or refractory chronic lymphocytic leukemia (r/r cll) or small lymphocytic lymphoma (sll).


Eligibility criteria:
inclusion criteria: * participants with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) and high-risk features must have failed at least 2 lines of prior therapy and participants with cll or sll and standard risk features must have failed at least 3 lines of prior therapy * eastern cooperative oncology group (ecog) performance status of ≤ 1 * either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure * has recovery to grade ≤ 1 or baseline of any non-hematologic toxicities due to previous therapy, except alopecia (any grade acceptable) and peripheral neuropathy (grade ≤ 2 acceptable) exclusion criteria: * any condition, including active or uncontrolled infection, or the presence of laboratory abnormalities, that places the subject at unacceptable risk if they were to participate in the study * systemic fungal, bacterial, viral, or other infection that is not controlled * active autoimmune disease requiring immunosuppressive therapy * progressive deep vein thrombosis or pulmonary embolism requiring treatment, but not yet on a stable anticoagulation regimen other protocol-defined inclusion/exclusion criteria apply

Keywords: bms-986403 relapsed and/or refractory small lymphocytic lymphoma (cll) chronic lymphocytic leukemia (sll)
digital perineal massage and pelvic floor muscle exercise during pregnancy for prevention of perineal laceration

Conditions: Delivery; Injury, Maternal

Summary: pregnant participants will be recruited at the obstetrics outpatient clinic during their visits 4 weeks before the due date. they are randomized into two groups. the first group will be educated to do digital perineal massage. they will be also educated to do pelvic floor muscle exercises and will receive the usual education program for strengthening the pelvic floor. the second group will receive the usual education program for strengthening the pelvic floor. occurrence of perineal laceration will be reported at time of delivery.

pregnant participants will be recruited at the obstetrics outpatient clinic during their visits 4 weeks before the due date. they are randomized into two groups. the first group will be educated to do digital perineal massage. they will be also educated to do pelvic floor muscle exercises and will receive the usual educational pelvic floor dysfunction prevention program for strengthening the pelvic floor. the second group will receive the usual education program for strengthening the pelvic floor. occurrence of perineal laceration will be reported at time of delivery.

Eligibility criteria:
inclusion criteria: * pregnant women ≥ 35 years old * primigravida or multi gravida exclusion criteria: * history of chronic constipation * history of chronic cough * current or past urinary or anal incontinence * history of genital prolapse before pregnancy * history of neuromuscular disorders or connective tissue disorders * history of medical disorders * history of preterm or precipitate labour * history of premature preterm rupture of membranes. * genital infections
68ga-psma pet/ct or pet/mri in evaluating patients with recurrent prostate cancer

Conditions: Recurrent Prostate Carcinoma

Summary: this clinical trial studies gallium-68 (68ga)-prostate specific membrane antigen (psma) (gallium ga 68-labeled psma ligand glu-urea-lys\[ahx\]) positron emission tomography (pet)/computed tomography (ct) or pet/magnetic resonance imaging (mri) in identifying prostate cancer that may have returned after a period of improvement (biochemical recurrence). 68ga-psma is a radiopharmaceutical that localizes to a specific prostate cancer receptor, which can then be imaged by the pet/ct or pet/mri scanner.

primary objectives: evaluate the feasibility and biodistribution of 68ga-psma. outline: patients are injected with 5 mci of ga68 psma intravenously (iv) and then undergo pet/ct or pet/mri approximately 45 to 60 minutes later. after completion of study, patients are followed up at 24 hours and 1 week.

Eligibility criteria:
inclusion criteria: * provides written informed consent * known diagnosis of prostate cancer * patient has suspected recurrence based on biochemical data (prostate specific antigen \[psa\] \> 2 ng/ml) * able to remain still for duration of each imaging procedure (about one hour) exclusion criteria: * unable to provide informed consent * inability to lie still for the entire imaging time * inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance
multifaceted intervention for increasing performance of cpr by laypersons in out-of-hospital cardiac arrest

Conditions: Cardiac Arrest

Summary: cardiac arrest (ca) early recognition is essential in order to rapidly activate emergency services and for bystanders to begin cardiopulmonary resuscitation (cpr). as soon as a call is received, ems dispatchers should try to identify ca. this may be difficult, in a context of stress and distress of the person calling. yet, it is vital for bystanders to initiate cpr. survival can be multiplied by 2 to 4 if the bystanders initiate a cpr before the arrival of the emergency medical services. this work aim to assess a multifaceted intervention combining 3 elements to improve the initial phone recognition of ca and raise the number of patients benefiting from cpr before ems arrival on scene. the first element is a dispatcher training to the early phone recognition of ca. this training will be based on the concept of active teaching, favouring the interactive work of learners in particular by listening to real dispatch recordings. it will be completed by continuing education with a distance teaching platform including the systematic listening of recorded ca calls. the second element is based on the deployment of a software aiming to notify ca thanks to mobile phones. this system interfaced to a control software enables to request the participation of cpr-trained volunteers automatically. the volunteers have to be located in the patient's surroundings. the deployment of this mobile application will rely on first-aid volunteers, health personal and any trained volunteers willing to participate. a randomized control study in one city area proved the efficiency of a similar software to improve the proportion of cpr by bystanders. the third element consists in a motivational feedback. a weekly overview of the management and the outcomes of patients who suffered ca will be broadcast to all the responders and volunteers in the mobile application.


Eligibility criteria:
inclusion criteria: * all adults with nontraumatic, out-of-hospital cardiac arrest diagnosed during the emergency medical service call * cardiac arrest located in urban area exclusion criteria: * pregnant or breastfeeding women * patients under the law * patients deprived of liberty by court ruling or administrative ruling * traumatic cardiac arrest * ca occurring under the eyes of a professional emergency services patrol on duty * cardiac arrest for which resuscitation seem unjustified (inevitable death, terminally ill irreversible condition, too long duration of cardiac arrest, non-resuscitation personal directive...)

Keywords: cardiac arrest dispatcher cardiopulmonary resuscitation
bio-equivalence study with clinical endpoints in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: bio-equivalence study with clinical endpoints in the treatment of acne vulgaris

randomized, double-blind, multiple center placebo controlled study comparing taro product to rld and both treatments to a placebo control in the treatment of acne vulgaris

Eligibility criteria:
inclusion criteria: * healthy male or non pregnant female aged ≥ 12 and ≤ 40years with a clinical diagnosis of acne vulgaris. * subjects who are 18 years of age or older (up to the age of 40) must have provided irb approved written informed consent. * subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the investigator's global assessment (iga). exclusion criteria: * female subjects who are pregnant, nursing or planning to become pregnant during study participation * subjects with a history of hypersensitivity or allergy to adapalene, retinoids and/or any of the study medication ingredients, have a known hypersensitivity to adapalene and benzoyl peroxide and its excitements.
rehabilitation and prophylaxis of anomia in primary progressive aphasia

Conditions: Aphasia, Primary Progressive; Anomia; Alzheimer Disease

Summary: the goal of this study is to remediate word-finding problems in patients who have primary progressive aphasia (ppa) or alzheimer's disease and to delay the further progression of word-finding impairment. the current approach is novel in that it contains a prophylaxis component in which the investigators attempt to strengthen neural connections that remain functional, making them more resistant to degradation as the disease progresses. while the study is specific in its targeting of word-finding problems, a successful outcome would bode well for other studies aimed at prevention or reversal of declining cognitive functions in dementia. one set of participants with ppa will receive practice with picture naming in two conditions: viewing the picture and repeating the name; and viewing the picture with its written name, plus reading and writing the name. another set of participants with ppa or alzheimer's disease will be trained in two different conditions: learning about the word's semantic features (meaning); and learning about the word's lexical features (letters and sounds). naming of pictures trained in each of these conditions will be compared, at three time intervals post-training, with naming of pictures tested before the study but never trained. it is predicted that the pairing of the picture with its written name, combined with the motor task of writing the name, will result in a greater ability to name the picture at a later date than simple practice viewing the picture and repeating the name. furthermore, it is predicted that participants who have difficulty understanding concepts will be more likely to respond to semantic treatment, while participants who have difficulty connecting words with concepts will be more likely to respond to lexical treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of primary progressive aphasia (ppa; including frontotemporal dementia, semantic dementia, or a similar condition) or diagnosis of alzheimer's disease * at least 10 years of education * ability to follow spoken instructions * medically stable * first language is english, or fluent in english since childhood * willing to participate over a period of two years exclusion criteria: * no history of additional neurological problems * no history of substance abuse or psychiatric problems
occupational exposure to pesticides in the prognosis of lymphomas

Conditions: Lymphoma Diffuse Large B-cell

Summary: the link between the products of synthetic chemistry and cancer is at the heart of much research. recent work has identified the use of plant protection agents by farmers as a risk factor for developing non-hodgkin lymphoma, including diffuse large b cell lymphoma (dlbcl) is the most common histology. different biological models were used to understand the role of pesticides in lymphomagenesis. to summarize, most pesticides act at the cellular and molecular level, on different signaling pathways. after metabolized by cytochrome p450, these compounds generally become pro-oxidants. the increase in reactive oxygen species rate (sar) causes the activation of signaling pathways involved in cell proliferation and survival. but deregulation of oxidative status does not in itself justify the specificity of the impact of pesticides on specific pathologies. several agents have a genotoxic effect, others induce the activation of signaling pathways by binding to transcription factors and others have immunomodulating properties.

the link between the products of synthetic chemistry and cancer is at the heart of much research. recent work has identified the use of plant protection agents by farmers as a risk factor for developing non-hodgkin lymphoma, including diffuse large b cell lymphoma (dlbcl) is the most common histology. different biological models were used to understand the role of pesticides in lymphomagenesis. to summarize, most pesticides act at the cellular and molecular level, on different signaling pathways. after metabolized by cytochrome p450, these compounds generally become pro-oxidants. the increase in reactive oxygen species rate (sar) causes the activation of signaling pathways involved in cell proliferation and survival. but deregulation of oxidative status does not in itself justify the specificity of the impact of pesticides on specific pathologies. several agents have a genotoxic effect, others induce the activation of signaling pathways by binding to transcription factors and others have immunomodulating properties. among these four mechanisms by which pesticides are involved in lymphomagenesis, two are also associated with resistance to chemotherapy. thus, genotoxic agents leads the implementation process of dna repair, used to repair genotoxic lesions induced by chemotherapeutic agents and evade apoptosis. on the other hand, to survive a high level of ros, the tumor cell raises the level of antioxidant defenses, maintaining redox homeostasis and preventing oxidative stress. however, a high production of antioxidants constitutes a barrier to the effectiveness of anti-tumor agents which are effective in the generation of oxidative stress.

Eligibility criteria:
inclusion criteria: adults treated for diffuse large b-cell lymphoma: * diagnosed between 2010 and 2015 * having received immuno-chemotherapy r-chop * supported in the health facilities of the languedoc-rousillon exclusion criteria: na
pivotal trial of dermagraft(r) to treat venous leg ulcers

Conditions: Venous Leg Ulcer

Summary: this study randomly assigns patients with venous leg ulcers to receive standard therapy (compression) alone or compression plus dermagraft(r). dermagraft is a device containing live human fibroblasts grown on an absorbable vicryl mesh. patients are seen weekly until they heal or the 16-week treatment period is complete. follow-up visits are conducted monthly for three months in order to assess patients for longer term safety.


Eligibility criteria:
inclusion criteria: * \>18 years of age * abi \> 0.80 * three or fewer venous leg ulcers, if multiple must be separated by 2 cm * ultrasound demonstrates venous reflux \>0.5 seconds * study wound present for 1-24 months * study wound 2-15 sq cm surface area * clean, granulating wound * patient able and willing to sign informed consent and comply with study procedures. * women of childbearing potential must use birth control pills, barriers or abstinence and have a negative pregnancy test. exclusion criteria: * wound etiology uncertain or not from venous hypertension. * bmi\>40 * acute or chronic infectious skin disease * allergy or intolerance to profore(r) * wound infection, cellulitis, osteomyelitis * \>2 weeks' treatment with immunosuppressive agents in recent past * investigational drug use within 30 days * severe malnutrition, drug and/or alcohol abuse * malignant disease unless in remission for 5 years * history of radiation at the study site * other conditions that could impede wound healing * known history of hiv or aids * prior participation in any dermagraft study * treatment with other bioengineered tissue products within 30 days * unable to understand the aims and objectives of the trial * inability to comply with study protocol * nyha class iii or iv chf * uncontrolled diabetes mellitus * dorsal foot ulcer

Keywords: venous leg ulcer randomized trial clinical trial dermagraft compression therapy surgical debridement venous stasis chronic ulcer chronic wound fibroblasts
delving into participation patterns in social anxiety studies

Conditions: Social Anxiety

Summary: the study seeks to delve into the firsthand experiences of patients diagnosed with social anxiety who partake in a separate clinical trial featuring a specific medical intervention. the primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. by joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future social anxiety patients and play an active role in advancing medical research.


Eligibility criteria:
inclusion criteria: * patient has self-identified as planning to enroll in a clinical trial * patient has been diagnosed with social anxiety * patient is a minimum of 18 years or older exclusion criteria: * patient does not understand, sign, and return consent form * inability to perform regular electronic reporting * patient is pregnant

Keywords: social anxiety
chamaemelum nobile 2% versus placebo topic gel to treat oral lichen planus

Conditions: Oral Lichen Planus

Summary: oral lichen planus (olp) is a chronic inflammatory mucocutaneous disease characterized by outbreaks or flares. it affects 0.2-1.9% of the population. although the etiology is unknown, the pathogenesis of olp is known to involve an immune disorder, with epithelial damage caused by cytotoxic cd8 + lymphocytes. clinically, the disease is characterized by different types of lesions - papular, reticular and in the form of plaques - that can alternate with erosive and/or ulcerative areas. a variety of treatments have been proposed for olp: topical or systemic corticosteroids, cyclosporine, retinoids, azathioprine, tacrolimus, pimecrolimus, photochemotherapy and surgery. patients with symptomatic olp often require intensive therapy to reduce the signs and symptoms. the disease can produce considerable morbidity and alter patient quality of life, particularly in the presence of ulcerative lesions. there is no fully resolutive and effective treatment - the management strategy focusing on the use of drugs that counter tissue inflammation and the underlying immunological mechanisms. the main inconvenience of these treatments is represented by the side effects they usually produce.

the purpose of this study was to evaluate that if chamaemelum nobile a can be used in the treatment of oral lichen planus. this could be useful as chamaemelum nobile has no reported side effects and hence it can used in place of steroids which are commonly used for this condition and have many reported adverse effects.

Eligibility criteria:
inclusion criteria: 1. patients clinically \& histopathologically diagnosed to be suffering from oral lichen planus. 2. patients who had symptoms i.e. pain and/or burning sensation secondary to oral lichen planus. 3. patients not on any treatment for the same. in case they were, then such treatment was stopped and a washout period of two weeks was given. exclusion criteria: 1. patients suffering from any systemic disease/s like 2. patients with any other mucosal disease or any other skin disease which may be associated with oral lesions. 3. patients on any drug therapy which may cause lichen planus like lesions. 4. patients with findings of any physical or mental abnormality, which would interfere with or be affected by the study procedure. 5. patients with a known allergy or contraindication to study medications
at-home care for subjects with periodontitis

Conditions: Periodontitis; Dental Plaque

Summary: the effect of use of powered toothbrushing in patients exhibiting periodontal inflammation has been observed repeatedly in clinical studies conducted over a 20+ year period. whether these subjects also had periodontitis, or not, was not a collected data metric as it was outside the scope of the investigation. this study, therefore, will specifically include and document that a subject exhibits periodontitis upon study entry, and measure the ensuing response following professional treatment of scaling and root planing, followed by home use of the assigned study products (powered or manual toothbrushing).


Eligibility criteria:
inclusion criteria: * between the ages of 18-75 years * exhibiting stage i or ii periodontitis * minimum of 20 'scorable' teeth (excluding 3rd molars) * regular manual toothbrush user * have a minimum average plaque score of \> 1.8 per modified plaque index scoring with 3-6 hours plaque accumulation * agree to desist use of interproximal cleaning aids and other prohibited devices or medicaments during the study period * be a non-smoker (\> 10 years), or never smoker exclusion criteria: * have a cardiac pacemaker or implanted cardiac defibrillator * have uncontrolled insulin-dependent diabetes have current use of antibiotic medications or use within 4 weeks of enrollment * have current use of prescription-dose anti-inflammatory medications or anticoagulants have excessive gingival recession, per investigator/examiner discretion * have heavy deposits of calculus, either supragingival and/or subgingival, per investigator/examiner discretion * have had a professional prophylaxis within 4 weeks of the study * prior chemotherapy, immunotherapy or radiation therapy within last 10 years
guo's aortic arch reconstruction: the first in man study of weflow-arch modular embedded branch stent graft system

Conditions: Aortic Arch; Aneurysm, Dissecting

Summary: this study is the first in man study of weflow-arch module embedded aorta arch stent graft system

the weflow-arch moduler embedded aorta arch stent graft system first in man study is a prospective, single center, single arm trial, which will enroll a total of 20 patients. the goal of this study is to evaluate the safety and efficacy of weflow-arch moduler embedded aorta arch stent graft system in the treatment of patients with lesions of the aortic arch.

Eligibility criteria:
inclusion criteria: 1. patients aged 18 to 85 years old； 2. diagnosed with aortic arch lesions requiring intervention, including true aortic arch aneurysms, pseudo-aortic arch aneurysms, dissection and ulcers involving the aortic arch; 3. the length of the ascending aorta is greater than 4cm (from the junction of the aortic sinus tube to the proximal edge of the innominate artery)； 4. ascending aorta diameter ≥24mm and ≤44mm； 5. the diameter of the iliac artery ≥7mm ； 6. the diameter of the innominate artery ≤24mm, and the length ≥20mm； 7. patients able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the subject him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol. exclusion criteria: 1. patients with ascending aortic aneurysm, dissection, ulcer, hematoma； 2. experienced systemic infection during past three months; 3. history of aortic valve repair or replacement； 4. history of aortic surgery or endovascular repair surgery； 5. carotid artery is severely narrowed, calcified, clotted, twisted； 6. right axillary artery is severely narrowed, calcified, thrombosis, twisted； 7. heart transplant； 8. suffered mi or stroke during past three months； 9. class iv heart function (nyha classification)； 10. pregnant or breastfeeding； 11. allergies to contrast agents； 12. life expectancy less than 12 months。

Keywords: aortic arch aneurysm dissecting ulcers